Stock Yards Bank & Trust Co. Has $416,000 Holdings in Cencora, Inc. $COR

Stock Yards Bank & Trust Co. grew its holdings in Cencora, Inc. (NYSE:COR) by 4.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,387 shares of the company’s stock after purchasing an additional 64 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Cencora were worth $416,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the business. Net Worth Advisory Group boosted its stake in shares of Cencora by 1.4% in the 1st quarter. Net Worth Advisory Group now owns 2,645 shares of the company’s stock valued at $736,000 after purchasing an additional 36 shares during the last quarter. Obermeyer Wealth Partners boosted its stake in shares of Cencora by 1.3% in the 1st quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company’s stock valued at $758,000 after purchasing an additional 36 shares during the last quarter. Grove Bank & Trust boosted its stake in shares of Cencora by 4.3% in the 2nd quarter. Grove Bank & Trust now owns 879 shares of the company’s stock valued at $264,000 after purchasing an additional 36 shares during the last quarter. U.S. Capital Wealth Advisors LLC boosted its stake in shares of Cencora by 0.4% in the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock valued at $2,563,000 after purchasing an additional 38 shares during the last quarter. Finally, Cromwell Holdings LLC boosted its stake in shares of Cencora by 9.5% in the 1st quarter. Cromwell Holdings LLC now owns 450 shares of the company’s stock valued at $125,000 after purchasing an additional 39 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

Shares of COR opened at $302.54 on Friday. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $315.23. The firm’s 50 day moving average price is $294.68 and its two-hundred day moving average price is $290.25. The firm has a market cap of $58.66 billion, a P/E ratio of 31.13, a PEG ratio of 1.41 and a beta of 0.63.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, beating analysts’ consensus estimates of $3.79 by $0.21. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm had revenue of $80.66 billion for the quarter, compared to analyst estimates of $80.34 billion. During the same quarter in the previous year, the firm posted $3.34 earnings per share. The business’s revenue was up 8.7% on a year-over-year basis. On average, analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Friday, August 15th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.7%. Cencora’s payout ratio is presently 22.63%.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction that occurred on Thursday, September 18th. The shares were sold at an average price of $290.00, for a total transaction of $1,478,130.00. Following the completion of the sale, the chief executive officer owned 39,274 shares in the company, valued at $11,389,460. This trade represents a 11.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,993 shares of company stock worth $16,292,923. Insiders own 10.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Cencora in a research note on Saturday, September 27th. Jefferies Financial Group lifted their price objective on shares of Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a research note on Monday, June 30th. Morgan Stanley set a $330.00 price objective on shares of Cencora and gave the stock an “equal weight” rating in a research note on Wednesday, July 16th. Finally, Wells Fargo & Company lifted their price objective on shares of Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 13th. Ten research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Cencora has an average rating of “Moderate Buy” and an average target price of $311.25.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.